Syncor posts healthy 1998 numbers
Radiopharmaceutical firm Syncor International reported strong financial results this month, posting fourth quarter (end-December) net income of $3.5 million, up from 1997’s $1.7 million. Net sales for the quarter increased 25% to $119 million, up
Radiopharmaceutical firm Syncor International reported strong financial results this month, posting fourth quarter (end-December) net income of $3.5 million, up from 1997s $1.7 million. Net sales for the quarter increased 25% to $119 million, up from $94.8 million. The Woodland Hills, CA, company enjoyed net sales for the year of $449 million, up 18% from $380.6 million in 1997, and net income of $13.9 million, compared with $11.1 million the year before.
Syncor attributed its healthy results to its first price increase in six years, as well as its effort to control costs, which improved its gross margins. The company increased its operating income for its radiopharmacy business in 1998 to $21.4 million, up 64% from $13 million in 1997. In addition, Syncors imaging center subsidiary, Comprehensive Medical Imaging, contributed $37.5 million in sales to the company in fiscal 1998.
ASCO: Study Reveals Significant Racial/Ethnic Disparities with PSMA PET Use for Patients with mPCa
May 30th 2025Latinx patients with metastatic prostate cancer were 63 percent less likely than non-Hispanic White patients to have PSMA PET scans, according to a study of 550 patients presented at the American Society of Clinical Oncology (ASCO) conference.
Lunit Unveils Enhanced AI-Powered CXR Software Update
May 28th 2025The Lunit Insight CXR4 update reportedly offers new features such as current-prior comparison of chest X-rays (CXRs), acute bone fracture detection and a 99.5 percent negative predictive value (NPV) for identifying normal CXRs.
New MRI Study Questions Use of Corticosteroid Injections for Knee OA
May 27th 2025Two years after intraarticular knee injections for knee osteoarthritis (OA), study participants who had corticosteroid knee injections had greater OA progression than control patients while the use of hyaluronic acid injections was associated with less OA progression.
